Genmab Announces Changes to its Executive Committee
16 août 2024 09h00 HE
|
Genmab A/S
Media Release COPENHAGEN, Denmark; August 16, 2024 Rayne Waller joins as Executive Vice President and Chief Technology OfficerBrad Bailey appointed as Executive Vice President and Chief...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
13 août 2024 14h53 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; August 13, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
13 août 2024 14h51 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; August 13, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 28,193 shares as a consequence of the exercise of employee warrants. The...
Genmab Announces Financial Results for the First Half of 2024
08 août 2024 11h03 HE
|
Genmab A/S
August 8, 2024 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2024 Highlights Completed acquisition of ProfoundBio Inc (ProfoundBio), granting Genmab worldwide rights to...
Genmab Updates 2024 Financial Guidance
08 août 2024 11h00 HE
|
Genmab A/S
Company Announcement Genmab updates its 2024 financial guidanceIncrease in revenue driven by higher royalties and reimbursement revenueIncrease in operating profit excluding acquisition and...
Genmab Takes Full Control of Acasunlimab Development Program
05 août 2024 05h50 HE
|
Genmab A/S
Company Announcement Genmab to assume sole responsibility for the continued development and potential commercialization of acasunlimab BioNTech has opted not to participate in the further development...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024
17 juil. 2024 06h25 HE
|
Genmab A/S
Company Announcement Net sales of DARZALEX® in the second quarter of 2024 totaled USD 2,878 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN,...
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
28 juin 2024 02h00 HE
|
Genmab A/S
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE® NHL-1 studyFL is the second most common type of NHL and accounts for approximately 20-30 percent of all global...
Completion of Share Buy-back Program
27 juin 2024 17h00 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 27, 2024 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on June 26, 2024. On March 15, 2024, Genmab announced...
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
26 juin 2024 19h03 HE
|
Genmab A/S
Company Announcement Approval based on results from Phase 1/2 EPCORE® NHL-1 study, which demonstrated durable, clinically meaningful treatment responses in patients with challenging-to-treat R/R FL...